GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.

ABSTRACT:

SUBMITTER: Sievers P 

PROVIDER: S-EPMC8568855 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature